Thermo Fisher Scientific (TMO) has seen its share price pull back by 18% in the last month, prompting investors to re-evaluate its valuation. Despite the recent decline, the company is considered “undervalued” with a fair value of $540.27 compared to its current price of $515.60. The article suggests TMO is well-positioned for future growth driven by R&D, emerging markets, and M&A, but also highlights risks like tightening R&D budgets or acquisition integration issues.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Assessing Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Pullback
Thermo Fisher Scientific (TMO) has seen its share price pull back by 18% in the last month, prompting investors to re-evaluate its valuation. Despite the recent decline, the company is considered “undervalued” with a fair value of $540.27 compared to its current price of $515.60. The article suggests TMO is well-positioned for future growth driven by R&D, emerging markets, and M&A, but also highlights risks like tightening R&D budgets or acquisition integration issues.